Evidence map›Paper›PMID 28922365›Full record

ArticlePloS one2017

Isothiocyanate-enriched moringa seed extract alleviates ulcerative colitis symptoms in mice.

Youjin Kim, Alex G Wu, Asha Jaja-Chimedza, Brittany L Graf, Carrie Waterman, Michael P Verzi, Ilya Raskin

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
15.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 88 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Isothiocyanate-Rich Moringa Seed Extract Activates SKN-1/Nrf2 Pathway inInternational journal of molecular sciences · 2024
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Bioactive Compounds inPlants (Basel, Switzerland) · 2023
    Review
  15. Isothiocyanate-rich moringa seed extract reduces skin inflammation in mouse ear edema model.Phytomedicine plus : international journal of phytotherapy and phytopharmacology · 2023
    Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Youjin KimNutrasorb, LLC., Freehold, New Jersey, United States of America.ORCID http://orcid.org/0000-0001-8960-3489
Alex G WuDepartment of Genetics and the Human Genetics Institute of New Jersey, Rutgers, The State University of New Jersey, Piscataway Township, New Jersey, United States of America.
Asha Jaja-ChimedzaDepartment of Plant Biology, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States of America.
Brittany L GrafDepartment of Plant Biology, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States of America.
Carrie WatermanDepartment of Nutrition, University of California-Davis, Davis, California, United States of America.
Michael P VerziDepartment of Genetics and the Human Genetics Institute of New Jersey, Rutgers, The State University of New Jersey, Piscataway Township, New Jersey, United States of America.
Ilya RaskinDepartment of Plant Biology, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States of America.
Rutgers, The State University of New Jersey · USUniversity of California, Davis · US

Funding

Pregnane and Glycosides and Obesity/llya RaskinP50AT002776 · NCCIH · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI FLOYD, ZELPHA ELIZABETH, STEPHENS, JACQUELINE M · 2005 to 2019
$24.9M
Training in Botanical Approaches to Combat Metabolic SyndromeT32AT004094 · NCCIH · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI BRANTLEY, PHILLIP J, STEPHENS, JACQUELINE M · 2009 to 2024
$5.7M
Reducing the burden of chronic inflammation through dietary integration of Moringa oleiferaK01TW009987 · FIC · UNIVERSITY OF CALIFORNIA AT DAVIS · PI WATERMAN, CARRIE · 2015 to 2019
$746k
Stable, antiinflammatory isothiocyanates from moringa may prevent and treat IBDR43AT008628 · NCCIH · NUTRASORB, LLC · PI KIM, YOUJIN · 2015 to 2017
$212k
FIC NIH HHS K01 TW009987NCCIH NIH HHS P50 AT002776NCCIH NIH HHS R43 AT008628NCCIH NIH HHS T32 AT004094
6 · The paper itself

Abstract

Moringa (Moringa oleifera Lam.) seed extract (MSE) has anti-inflammatory and antioxidant activities. We investigated the effects of MSE enriched in moringa isothiocyanate-1 (MIC-1), its putative bioactive, on ulcerative colitis (UC) and its anti-inflammatory/antioxidant mechanism likely mediated through Nrf2-signaling pathway. Dextran sulfate sodium (DSS)-induced acute (n = 8/group; 3% DSS for 5 d) and chronic (n = 6/group; cyclic rotations of 2.5% DSS/water for 30 d) UC was induced in mice that were assigned to 4 experimental groups: healthy control (water/vehicle), disease control (DSS/vehicle), MSE treatment (DSS/MSE), or 5-aminosalicyic acid (5-ASA) treatment (positive control; DSS/5-ASA). Following UC induction, water (vehicle), 150 mg/kg MSE, or 50 mg/kg 5-ASA were orally administered for 1 or 2 wks. Disease activity index (DAI), spleen/colon sizes, and colonic histopathology were measured. From colon and/or fecal samples, pro-inflammatory biomarkers, tight-junction proteins, and Nrf2-mediated enzymes were analyzed at protein and/or gene expression levels. Compared to disease control, MSE decreased DAI scores, and showed an increase in colon lengths and decrease in colon weight/length ratios in both UC models. MSE also reduced colonic inflammation/damage and histopathological scores (modestly) in acute UC. MSE decreased colonic secretions of pro-inflammatory keratinocyte-derived cytokine (KC), tumor necrosis factor (TNF)-α, nitric oxide (NO), and myeloperoxidase (MPO) in acute and chronic UC; reduced fecal lipocalin-2 in acute UC; downregulated gene expression of pro-inflammatory interleukin (IL)-1, IL-6, TNF-α, and inducible nitric oxide synthase (iNOS) in acute UC; upregulated expression of claudin-1 and ZO-1 in acute and chronic UC; and upregulated GSTP1, an Nrf2-mediated phase II detoxifying enzyme, in chronic UC. MSE was effective in mitigating UC symptoms and reducing UC-induced colonic pathologies, likely by suppressing pro-inflammatory biomarkers and increasing tight-junction proteins. This effect is consistent with Nrf2-mediated anti-inflammatory/antioxidant signaling pathway documented for other isothiocyanates similar to MIC-1. Therefore, MSE, enriched with MIC-1, may be useful in prevention and treatment of UC.

Indexed as

AnimalsChronic DiseaseClaudin-1Colitis, UlcerativeColonCytokinesDextran SulfateIsothiocyanatesLipocalin-2MaleMiceMoringaNF-E2-Related Factor 2Nitric OxideNitric Oxide Synthase Type IIPeroxidaseClaudin-1Cldn1 protein, mouseCytokinesDextran SulfateIsothiocyanatesisothiocyanic acidLcn2 protein, mouseLipocalin-2Nfe2l2 protein, mouseNF-E2-Related Factor 2Nitric OxideNitric Oxide Synthase Type IINos2 protein, mousePeroxidasePlant ExtractsTjp1 protein, mouseZonula Occludens-1 Protein

Identifiers

PMID28922365
PMCPMC5602518
OpenAlexW2755831240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.